MedTrace Logo

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

NCT05799612 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2026-02-13

No results posted yet for this study

Summary

To find the highest tolerable dose of an mRNA vaccine that can be safely given to patients with cutaneous angiosarcoma

Conditions

  • Angiosarcoma

Interventions

DRUG

Paclitaxel

Given by IV (vein)

BIOLOGICAL

mRNA plus Lysate-loaded Dendritic Cell Vaccine

Given by IV (vein)

DRUG

PEGYLATED-INTERFERON ALPHA-2A

Given by IV (vein)

DRUG

Filgrastim

Given by IV (vein)

Sponsors & Collaborators

  • Cancer Cures 4 Kids

    collaborator UNKNOWN

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Vinod Ravi, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-22
Primary Completion
2024-11-05
Completion
2024-11-05
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05799612 on ClinicalTrials.gov